Understanding IVF Success Rates: How They Are Measured
Key Takeaways
IVF success rates are reported in several different ways — per cycle started, per egg retrieval, per embryo transfer, and cumulatively across linked transfers — so two clinics can quote very different numbers for the same patient. In its 2019 report, ESHRE/EIM reported a clinical pregnancy rate of about one-third per fresh transfer, but this is a population average, not an individual forecast. Personal planning needs the endpoint, denominator, age group, and relevant clinical factors to be stated clearly.
Key evidence: ESHRE/EIM — ART in Europe, 2019 SART — National Summary Report (2022 US Data) ASRM Practice Committee — Ovarian Reserve & Prognosis (2020)
When patients ask me, “Doctor, what is your success rate?”, I understand exactly what they are hoping for: a single, reassuring number they can hold on to. I wish the answer were that simple. It is one of the most natural questions in fertility care, yet also one of the easiest to answer in a misleading way.
The truth is that “IVF success rate” is not a single figure. It is a family of different measurements. The number a clinic displays on its website can vary dramatically depending on which metric it selects, who it counts, and which patients are included in the denominator. Before you compare clinics or plan your treatment, it is vital to understand what these numbers actually describe — and, just as importantly, what they cannot tell you about your personal prognosis.
Why IVF success rates are not a single number
There is no single universal “success rate” because outcomes can be measured at several distinct milestones in the treatment journey, each producing a different percentage:
- Per cycle started: Includes every patient who begins ovarian stimulation medications, including those who cancel before egg retrieval.
- Per egg retrieval (oocyte pick-up): Measures success among patients who reached egg collection, excluding early cancellations.
- Per embryo transfer: Calculates success only among patients who reached the transfer stage with an embryo available for transfer. This figure can be higher because cancelled stimulations and cycles without a transferable embryo are removed from the denominator; it is not directly comparable with a rate per cycle started.
- Cumulative live birth rate (CLBR): Tracks the probability of a live birth across all fresh and frozen embryo transfers resulting from a single egg retrieval.
The term pregnancy rate also needs a definition. It may refer to a biochemical pregnancy confirmed by a positive hCG test or to a clinical pregnancy confirmed by ultrasound. A live birth rate counts a baby born alive. When the population and denominator are the same, the live birth rate is generally lower because some pregnancies end before birth.
The three questions every patient should ask when looking at a statistic are:
- Is this number per cycle started, per retrieval, or per transfer?
- Does “pregnancy” mean a biochemical or ultrasound-confirmed clinical pregnancy, or is the endpoint live birth?
- Which specific age group does this percentage represent?
Without these three clarifications, an isolated percentage tells you very little.
How clinics report outcomes — and what to compare
To compare two clinics fairly, you must ensure they are measuring the exact same outcome, in the same way, across comparable patient populations.
Key reporting variables include:
- Registry versus in-house data: National and European registries enforce strict, standardised definitions. In-house statistics published on marketing pages may use selective denominators.
- Per transfer versus per retrieval: Per-transfer figures exclude patients who never generated a transferable embryo, so they can make a clinic’s headline rate look higher than its rate per retrieval.
- Fresh versus frozen transfer: Observed rates after frozen transfer are influenced by patient selection, freeze-all policies, embryo stage, and the timing of transfer. Randomized evidence suggests little or no difference in cumulative live birth between a freeze-all strategy and conventional treatment for an unselected population. The decision can still be useful in specific clinical situations. See our guide on fresh versus frozen embryo transfer and the Cochrane review on fresh versus frozen transfer.
- Cumulative live birth rate (CLBR): This can be a useful cycle-level measure when the retrieval, linked transfers, follow-up window, and denominator are clearly defined. It is not automatically comparable across registries.
- Age stratification: Maternal age is a major biological determinant of IVF outcome. A statistic without an age breakdown is difficult to interpret for an individual patient.
A clinic treating predominantly younger patients with less complex diagnoses will naturally display higher overall success rates than a tertiary centre specialising in advanced maternal age, diminished ovarian reserve, or repeated implantation failure — without necessarily providing better care.
What European registry data show
Across Europe, registry averages differ by endpoint and denominator. In the ESHRE/EIM report on 2019 cycles, the clinical pregnancy rate per fresh transfer was roughly one-third, with lower delivery rates per transfer.
The European IVF Monitoring Consortium (EIM), coordinated by the European Society of Human Reproduction and Embryology (ESHRE), gathers national registry data across Europe. In the report on 2019 cycles, the pregnancy rate per fresh transfer was 34.6% for conventional IVF and 33.5% for ICSI, with delivery rates per transfer of 25.3% and 24.1%, respectively. Frozen embryo transfers had a pregnancy rate of 35.8% and a delivery rate of 25.6% per transfer. These are European multi-centre averages, not a clinic-specific or individual prognosis.
| Measure (European registry, per transfer) | IVF | ICSI | Frozen transfer (FET) |
|---|---|---|---|
| Pregnancy rate | ~34.6% | ~33.5% | ~35.8% |
| Delivery rate | ~25.3% | ~24.1% | ~25.6% |
Source: ESHRE/EIM European Registry Report on 2019 cycles. Figures represent European multi-centre averages per embryo transfer and are not specific to any single clinic.
These overall averages conceal a strong age gradient. Outcomes tend to be higher in younger age groups and lower after 40, but biology does not change at one exact birthday. The ESHRE report should therefore be read as a population summary, not as a personal forecast.
The preliminary ESHRE/EIM data for 2022 use several different endpoints: clinical pregnancy per aspiration was 24.2% for IVF and 23.3% for ICSI, clinical pregnancy per transfer was 45.7% and 45.4%, and pregnancy per thawing after FET was 31.8%. These figures should not be merged into the 2019 per-transfer table because their denominators differ.
A US benchmark for context
US national data provide a complementary perspective by reporting outcomes per intended egg retrieval, including linked embryo transfers within the report’s defined follow-up period.
The Society for Assisted Reproductive Technology (SART) reports US national outcomes. For 2022 cycles using patients’ own eggs, the live birth rate per intended egg retrieval after all embryo transfers showed a clear age gradient:
| Maternal age | Live birth rate per intended retrieval, all embryo transfers (US SART, 2022) |
|---|---|
| Under 35 | 53.5% |
| 35–37 | 39.8% |
| 38–40 | 25.6% |
| 41–42 | 13.0% |
| Over 42 | 4.5% |
Source: SART National Summary Report, 2022 cycles, own eggs. The all-transfer endpoint combines the first and subsequent linked transfers within the report’s follow-up window, and includes cycles that did not reach transfer. It is methodologically distinct from the European per-transfer table.
While European and US registries group data differently and cannot be directly compared, both show a strong age gradient. Age is a major biological predictor, but neither registry table determines an individual prognosis.
What actually determines your individual odds?
A registry average describes a broad population. Your personal prognosis depends on a specific combination of clinical and biological variables:
- Maternal age: Strongly influences the probability that an embryo will be chromosomally euploid.
- Ovarian reserve (AMH and Antral Follicle Count): Helps estimate ovarian response and the number of eggs we may retrieve. It is not a direct measure of egg quality and should not be used alone to predict live birth, as explained in the ASRM committee opinion on ovarian reserve. Our guide on how many eggs you need for IVF success explains why egg number creates more opportunities to reach a transferable embryo.
- Semen analysis and selected male-factor tests: Concentration, progressive motility, and morphology are assessed routinely. Sperm DNA fragmentation is not recommended as a routine initial test; according to the AUA/ASRM male infertility guideline, it may be considered in selected clinical contexts.
- Prior cycle response: How your ovaries previously responded to stimulation protocols and the resulting fertilization and blastocyst conversion rates.
- Uterine and endometrial health: Cavity shape, absence of polyps or submucosal fibroids, and optimal lining preparation in frozen embryo transfer protocols.
- Embryo development and genetics: Blastocyst expansion grades and, where clinically indicated, preimplantation genetic testing.
Because these factors interact, two women of the same age can have meaningfully different clinical prognoses.
Dr. Aksoy’s clinical perspective
Dr. Aksoy’s approach: realistic planning, not marketing percentages
“When a patient asks me, ‘Another clinic advertises a 70% success rate, what is yours?’, my first question is: 70% of what? Is that a positive pregnancy test, a single transfer of a selected blastocyst, or a cumulative live birth rate after using fresh and frozen embryos from one retrieval? These are different clinical endpoints.
Clinic-wide headline rates also depend heavily on patient selection and age distribution. In consultation, I focus on two numbers: the realistic live birth probability per transfer, and the cumulative live birth probability across the embryos from that retrieval within a defined follow-up period.
Age is a major predictor because it is closely related to the probability that an embryo is chromosomally euploid. AMH, on the other hand, helps us estimate ovarian response and how many eggs we may obtain; it informs the likely length and demands of the process, not a simple ‘yes or no’ test of pregnancy. Between two patients of the same age, prognosis also reflects stimulation response, blastocyst yield, embryo genetics, sperm factors, prior IVF outcomes, and uterine or endometrial health.
If a patient asks, ‘Will it definitely work on the first try?’, I explain that I cannot promise this. A negative first cycle does not mean the treatment plan is exhausted. A clear, evidence-based plan helps us manage uncertainty step by step.”
— Dr. Senai Aksoy
Related reading
- Fresh vs. Frozen Embryo Transfer: What the Evidence Shows
- How Many Eggs Do You Need for IVF Success?
- Decoding Your IVF Lab Report: Embryo Grading Explained
Frequently asked questions
Is a higher “pregnancy rate” the same as a higher chance of a live birth?
No. A pregnancy rate may refer to a positive β-hCG test or an ultrasound-confirmed clinical pregnancy, depending on the registry. A live birth rate counts babies born alive. The two endpoints should not be compared until their definitions and denominators are clear.
Why does one clinic advertise a much higher success rate than another?
Differences in advertised rates can arise from the endpoint, denominator, age mix, and patient population rather than from medical superiority. A clinic reporting per-transfer rates or treating primarily younger cohorts may show a higher average than a centre reporting per cycle started or treating more complex cases.
What is a cumulative live birth rate (CLBR)?
The cumulative live birth rate measures the chance of a live birth across linked fresh and frozen embryo transfers originating from one retrieval, within a stated follow-up period. It can be a useful cycle-level measure, but the time window and denominator must be reported before two CLBR figures are compared.
How much does age affect IVF outcomes?
Age is a major predictor, but there is no single birthday at which prognosis changes abruptly. In the SART 2022 national data, live birth rates per intended retrieval decreased across successive age groups. An individual estimate still needs to account for the other clinical factors described above.
Can my doctor predict my exact personal success rate before treatment begins?
A clinician can provide a tailored prognostic range based on your age, ovarian reserve biomarkers (AMH/AFC), semen analysis, and medical history—but not an absolute guarantee.
Sources
- Smeenk J, Wyns C, De Geyter C, et al. ART in Europe, 2019: results generated from European registries by ESHRE. Human Reproduction 2023;38(12):2321–2338.
- Wyns C, De Geyter C, Kupka MS, et al. ART in Europe, 2020: results generated from European registries by ESHRE. Human Reproduction 2025;40(11):2038–2057.
- de Neubourg D, Smeenk J, Cuevas I, et al. ART in Europe, 2022: preliminary results generated from European registers by the ESHRE EIM consortium. Human Reproduction 2025;40(Suppl 1):deaf097.159.
- European Society of Human Reproduction and Embryology (ESHRE). ART Fact Sheet and EIM Registry Resources.
- Society for Assisted Reproductive Technology (SART). National Summary Report (2022 Data).
- Practice Committee of the American Society for Reproductive Medicine (ASRM). Testing and interpreting measures of ovarian reserve: a committee opinion. Fertility and Sterility 2020;114(6):1151–1157.
- American Urological Association and American Society for Reproductive Medicine. Diagnosis and treatment of infertility in men: AUA/ASRM guideline, Part I. 2020.
- Zaat T, Zagers M, Mol F, et al. Fresh versus frozen embryo transfers in assisted reproduction. Cochrane Database of Systematic Reviews 2021;2:CD011184.
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.